Evotec Se's Comment on Sales, Marketing and Customers
The company provides services to customers in the USA and Europe, including molecular design, upstream and downstream processing, analytical and formulation development, and GMP manufacturing of biologics from first-in-human to commercial scale. JEB is a major customer, representing 33% of third-party revenues in 2025. The Discovery & Preclinical Development (D&PD) segment offers drug discovery and preclinical development services such as target validation, lead optimization, and IND application transition. Revenues in this segment are generated under the Evotec and Cyprotex brands through fee-for-service and collaboration agreements. The company serves as an external innovation partner to the life science industry, conducting multi-year, multi-stage drug discovery and development campaigns. The primary revenue source is fee-for-service, with milestone payments accounting for a smaller portion of total revenues. The company focuses on strategic pipeline development and co-ownership of drug products via proprietary technologies and intellectual property. Customers and markets mentioned include Cyprotex, Evotec, and JEB.
Evotec Se’s Comment on Sales, Marketing and Customers
The company provides services to customers in the USA and Europe, including molecular design, upstream and downstream processing, analytical and formulation development, and GMP manufacturing of biologics from first-in-human to commercial scale. JEB is a major customer, representing 33% of third-party revenues in 2025. The Discovery & Preclinical Development (D&PD) segment offers drug discovery and preclinical development services such as target validation, lead optimization, and IND application transition. Revenues in this segment are generated under the Evotec and Cyprotex brands through fee-for-service and collaboration agreements. The company serves as an external innovation partner to the life science industry, conducting multi-year, multi-stage drug discovery and development campaigns. The primary revenue source is fee-for-service, with milestone payments accounting for a smaller portion of total revenues. The company focuses on strategic pipeline development and co-ownership of drug products via proprietary technologies and intellectual property. Customers and markets mentioned include Cyprotex, Evotec, and JEB.
Sources:
Evotec Se’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Evotec Se’s corporate clients.
For your research, we’ve provided 9 tables on Evotec Se corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
65.66 %